As an example, a phase I/II trial of the mTOR inhibitor temsirolimus in combination with the Akt inhibitor and immunomodulatory agent lenalidomide in relapsed/refractory lymphomas demonstrated an ORR of 67% in 9 patients with T-cell lymphomas, a superior ORR compared to single-agent mTOR inhibition or lenalidomide alone [78]. The gene discussed is AKT1; the disease is T-cell non-Hodgkin lymphoma.